SINGAPORE and PENANG, Malaysia — Lucence and Partners Pathology have partnered to expand access to cancer diagnostics and personalized medicine in Malaysia. This commercial partnership combines Lucence’s molecular testing with Partners Pathology’s histopathology services to provide enhanced cancer detection and treatment selection.

Partners Pathology will offer Lucence’s suite of liquid and tissue biopsy tests, including LiquidHALLMARK®, which analyzes 80 ctDNA genes and 37 ctRNA fusions for clinically relevant biomarkers. The partnership establishes Penang as a medical hub, enabling access to comprehensive precision medicine solutions for both local and international patients.

“By establishing a physical presence in Malaysia, we are making it easier for patients in the region to access advanced testing,” said Dr. Ivy Ho, Director of Partners Pathology.

“We look forward to providing clinicians and their patients with genomic insights to inform treatment decisions through our high-sensitivity testing,” added Dr. Tan Min-Han, Founder and CEO of Lucence.